Highlights from Zacks analyst blog: Pfizer, AbbVie, Eli Lilly and J&J


For immediate release

Chicago, IL – January 10, 2022 – Zacks.com announces the list of stocks featured on the Analysts Blog. Every day, Zacks Equity Research analysts discuss the latest news and events impacting stocks and financial markets. Recent stocks featured in the blog include: Pfizer PFE, AbbVie ABBV, Eli Lilly LLY and J&J JNJ

Here are highlights from Friday’s analyst blog:

Pharmaceutical Stocks Review: Earnings Season Edition Ahead of Q4

This week, the FDA granted emergency approval to Pfizerbooster dose for children 12 to 15 years of age and granted the Revolutionary Therapy (“BTD”) designation to AbbViecandidate for lung cancer. Eli lilly announced a small collaboration agreement. NOT A WORD agreed to a $ 63 million settlement with Nevada to resolve their opioid-related claims.

Recap of the most important stories of the week

FDA Approves Pfizer’s COVID Jab Booster for 12-15 Year Olds: The FDA has extended the emergency use authorization (EUA) for the booster dose of Pfizer / BioNTech’s COVID-19 vaccine to allow its use in adolescents 12 to 15 years of age.

Along with the approval for 12 to 15 year olds, the FDA also amended the existing EUA to reduce the time between the end of the primary series and the booster dose for all eligible people who took a Pfizer vaccine to five. months instead of six months previously. . The FDA has also cleared a third dose of the primary series for children aged 5 to 11 who are immunocompromised.

The booster dose from Pfizer and BioNTech received emergency FDA approval in November 2021 for all adults 18 years of age and older, following completion of the primary series with any authorized or approved COVID-19 vaccine. FDA. In December, the EUA was extended to allow its use in people aged 16 and 17.

Meanwhile, the Centers for Disease and Control Prevention (CDC) has recommended Pfizer / BioNTech booster shots for anyone over 12 years of age, five months after their first round of Pfizer / BioNTech vaccinations.

Pfizer and BioNTech have signed a new collaboration to develop an mRNA-based vaccine for the prevention of shingles after experiencing success with their COVID-19 vaccine. Clinical studies of the mRNA-based shingles vaccine are expected to begin in the second half of 2022. The companies will manufacture the vaccine by taking advantage of Pfizer’s antigen technology and proprietary mRNA platform technology. BioNTech, which was used to make their successful COVID-19 vaccine. .

For the deal, Pfizer will make an upfront payment of $ 225 million to BioNTech that will include an upfront cash payment of $ 75 million and a capital investment of $ 150 million. This is the third collaboration between Pfizer and BioNTech on an mRNA vaccine.

Revolutionary FDA Label for AbbVie’s New Lung Cancer Candidate: AbbVie’s investigational antibody-drug conjugate (ADC) telisotuzumab vedotin (Teliso-V) has been granted a BTD for AbbVie wild-type non-small cell lung cancer (NSCLC) previously treated in patients with elevated levels overexpression of c-Met. Teliso-V is being studied in a phase II LUMINOSITY study in patients with second- or third-line NSCLC with overexpression of c-Met, while a phase III study is expected to start in the first half of 2022.

J&J Nevada Opioid Settlement Agreement:J&J has announced a $ 63 million settlement agreement with the state of Nevada in its opioid-related lawsuits. The settlement is under the terms of a previous nationwide opioid settlement agreement reached by J&J to pay approximately $ 5 billion over nine years to settle all opioid-related lawsuits in federal courts and states of the United States.

J&J faces thousands of lawsuits related to the abuse of its opioid-based drugs, including Duragesic, Nucynta and Nucynta ER. The lawsuits claim that J&J is one of many companies whose opioid drugs have fueled the state’s opioid epidemic.

J&J announced data from a real-world study, which showed that its single-injection COVID-19 vaccine protects against breakthrough infections and hospitalizations for up to six months. J&J observed a modest decrease in protection against breakthrough infections from month 4 of the study period. For mRNA vaccines, protection against breakthrough infections decreased at a higher rate for each month of follow-up.

Lilly’s new offering for neurological therapies: Lilly has licensed the rights to Entos Pharmaceuticals’ Fusogenix nucleic acid delivery technology to research and develop innovative therapies in multiple neurological indications. The companies will develop proteolipid vehicles (PLVs) for the delivery of Lilly’s therapeutic cargo to targets in the central and peripheral nervous systems.

While Entos will take care of the generation, development and optimization of the POS, Lilly will select the POS for clinical development and commercialization. For the deal, Lilly will make an upfront payment of $ 50 million to Entos, including a capital investment. Entos will also be entitled to receive up to $ 400 million in potential development and commercialization milestone payments.

The NYSE ARCA Pharmaceutical index has fallen 2.9% over the past five trading days.

Large-cap pharmaceutical industry 5 years return in%

Over the past five trading days, Merck has risen the most (2.2%) while Lilly has fallen the most (6.4%).

In the past six months, Pfizer recorded the highest gain (42.2%) while Novartis fell the most (4.4%)

(See the latest summary of pharmaceutical actions here: FDA approves oral PFE and MRK pills for COVID and other drugs)

What’s the next step in the pharmaceutical world?

Watch for regular updates on pipelines and regulations next week.

Zacks names “best single choice to overtake”

Among thousands of stocks, 5 Zacks experts each chose their favorite to skyrocket + 100% or more in the coming months. Of these 5, research director Sheraz Mian chooses one to have the most explosive advantage of all.

As one investor put it, “Cure and prevent hundreds of diseases… what should this market be worth? This company could compete with or surpass other recent Zacks stocks which are expected to double as Boston Beer Company which climbed + 143.0% in just over 9 months and NVIDIA which climbed + 175.9% in one. year.

Free: see our best stock and 4 finalists >>

Media contact

Zacks investment research

800-767-3771 ext 9339

[email protected]


Past performance is no guarantee of future results. The potential for loss is inherent in any investment. This material is provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold any security. No recommendation or advice is given as to whether an investment is suitable for a particular investor. It should not be assumed that any investment in any identified and described securities, companies, sectors or markets was or will be profitable. All information is current as of the date hereof and is subject to change without notice. The views or opinions expressed may not reflect those of the company as a whole. Zacks Investment Research does not engage in investment banking, market making or securities asset management activities. These returns come from hypothetical portfolios composed of stocks with a Zacks rank = 1 that have been rebalanced monthly without any transaction costs. These are not the returns of actual equity portfolios. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for more information on the performance numbers displayed in this press release.

Zacks’ top picks for leveraging artificial intelligence

By 2021, this world-changing technology is expected to generate $ 327.5 billion in revenue. Now Shark Tank star and billionaire investor Mark Cuban has said AI will create “the world’s first trillionaires.” Zacks’ Urgent Special Report Reveals 3 AI Choices Investors Need To Know Today.

See 3 artificial intelligence stocks with extreme upside potential >>

Click to get this free report

Johnson & Johnson (JNJ): Free Stock Analysis Report

Pfizer Inc. (PFE): Free Inventory Analysis Report

Eli Lilly and Company (LLY): Free Stock Analysis Report

AbbVie Inc. (ABBV): Free Stock Analysis Report

To read this article on Zacks.com, click here.

Zacks investment research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


Comments are closed.